Press coverage about Petmed Express (NASDAQ:PETS) has been trending positive recently, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Petmed Express earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.031569676229 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

A number of research firms recently weighed in on PETS. ValuEngine lowered Petmed Express from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Northcoast Research set a $58.00 price objective on Petmed Express and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Finally, BidaskClub raised Petmed Express from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $42.80.

Shares of Petmed Express stock traded up $0.06 on Thursday, reaching $44.72. The company’s stock had a trading volume of 29,423 shares, compared to its average volume of 664,254. Petmed Express has a 1-year low of $19.91 and a 1-year high of $57.80. The stock has a market cap of $913.04, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 2.50 and a beta of 0.93.

Petmed Express (NASDAQ:PETS) last issued its earnings results on Monday, January 22nd. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.33 by $0.11. Petmed Express had a return on equity of 34.04% and a net margin of 12.84%. The business had revenue of $60.10 million for the quarter, compared to the consensus estimate of $56.76 million. During the same period last year, the business posted $0.24 EPS. The company’s revenue was up 13.6% compared to the same quarter last year. research analysts forecast that Petmed Express will post 1.77 earnings per share for the current year.

In other Petmed Express news, CEO Menderes Akdag sold 30,000 shares of the stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the sale, the chief executive officer now directly owns 490,000 shares in the company, valued at approximately $24,990,000. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronald J. Korn sold 5,000 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $48.38, for a total value of $241,900.00. Following the sale, the director now owns 68,833 shares in the company, valued at $3,330,140.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,000 shares of company stock worth $2,341,900. Company insiders own 4.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/favorable-press-coverage-somewhat-unlikely-to-affect-petmed-express-pets-share-price/1957179.html.

About Petmed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Insider Buying and Selling by Quarter for Petmed Express (NASDAQ:PETS)

Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.